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Abstract
Background: Experimental evidence and clinical studies in breast cancer suggest that some anti-tumor therapy
regimens generate stimulation of the immune system that accounts for tumor clinical responses, however,
demonstration of the immunostimulatory power of these therapies on cancer patients continues to be a
formidable challenge. Here we present experimental evidence from a breast cancer patient with complete clinical
response after 7 years, associated with responsiveness of tumor specific T cells.
Methods: T cells were obtained before and after anti-tumor therapy from peripheral blood of a 63-years old
woman diagnosed with ductal breast cancer (HER2/neu+++, ER-, PR-, HLA-A*02:01) treated with surgery, followed
by paclitaxel, trastuzumab (suspended due to cardiac toxicity), and radiotherapy. We obtained a leukapheresis
before surgery and after 8 months of treatment. Using in vitro cell cultures stimulated with autologous monocyte-
derived dendritic cells (DCs) that produce high levels of IL-12, we characterize by flow cytometry the phenotype of
tumor associated antigens (TAAs) HER2/neu and NY-ESO 1 specific T cells. The ex vivo analysis of the TCR-Vβ
repertoire of TAA specific T cells in blood and Tumor Infiltrating Lymphocytes (TILs) were performed in order to
correlate both repertoires prior and after therapy.
Results: We evidence a functional recovery of T cell responsiveness to polyclonal stimuli and expansion of TAAs
specific CD8+ T cells using peptide pulsed DCs, with an increase of CTLA-4 and memory effector phenotype after
anti-tumor therapy. The ex vivo analysis of the TCR-Vβ repertoire of TAA specific T cells in blood and TILs showed
that whereas the TCR-Vβ04-02 clonotype is highly expressed in TILs the HER2/neu specific T cells are expressed
mainly in blood after therapy, suggesting that this particular TCR was selectively enriched in blood after anti-tumor
therapy.
Conclusions: Our results show the benefits of anti-tumor therapy in a breast cancer patient with clinical complete
response in two ways, by restoring the responsiveness of T cells by increasing the frequency and activation in
peripheral blood of tumor specific T cells present in the tumor before therapy.
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Background
Nowadays exists clinical evidence that the quality and
number of tumor infiltrating lymphocytes (TILs) is cru-
cial for clinical outcome of cancer patients [1]. On the
other hand, Kroemer and colleagues have published
abundant experimental evidence that suggests that some
chemo-radiotherapy regimens in cancer generate T cell
stimulation that accounts for the clinical response in-
duced by these therapies [2]. Despite all this experimen-
tal evidence, the demonstration of the stimulatory power
of the anti-tumor therapy (anti-TTx) on tumor-specific
T cells in cancer patients with complete response after
cancer treatment continues to be a formidable challenge.
The anergy induced early in the course of the tumors
[3], followed by tolerance and exhaustion of T cells
occurring late in a wide variety of solid tumors [4], to-
gether with the low frequency of T cells specific for
tumor associated antigens (TAAs) [5, 6] fosters the un-
responsiveness of T cells to tumor antigens that is one
important hurdles to monitor the response of T cells
specific for TAA in cancer patients during anti-TTx. The
design of in vitro systems that circumvent these obsta-
cles and that leads us into immunological readouts use-
ful to monitor the response of anti-tumoral T cells
during cancer treatment, may become instrumental in
establishing correlates between tumor outcome achieved
with these therapies and the response of T cells to
tumors in vivo. CD8+ T cells in peripheral blood are
themselves a complex mixture comprised of at least four
major subsets – naïve (TN), central memory (TCM), ef-
fector memory (TEM) and effector memory expressing
CD45RA (TEMRA) subsets – each having different
functional qualities [7]. Efforts have focused on identify-
ing traits of T cells in vitro that correlate with anti-
tumor responsiveness in vivo. TEMRA cells are devel-
oped from long-lasting memory cells and because their
potent effector cytolytic capacity they are the responsible
for tumor control. It is expected that evidencing the de-
velopment of TEMRA cells in vitro may be a reflection
of the generation of proficient anti-tumor immunity in
vivo [8, 9].
Geiger and colleagues attempted to overcome the lim-
ited detection capacity of functional T cell assays for the
detection of naïve and memory antigen (Ag)-specific T
cells in blood through the augmentation of the number
of these cells using in vitro expansion, however, this
approach is time consuming and requires considerable
manipulation [10]. To overcome these limitations, we
consider that the use of dendritic cells (DCs) induced
and matured in situ as antigen presenting cells (APCs),
using the standard maturation cocktail (stDCs) [11] or
the cytokine mix recently described for the induction of
Type I alpha DCs (aDCs) characterized by the produc-
tion of high levels of IL-12 [12] to activate memory T
cells [13] or to prime in vitro naïve T cells present in
peripheral blood mononuclear cells (PBMCs) [14], might
be a powerful approach for measuring the response of
tumor-specific T cells that expand in cancer patients in
response to anti-TTx. In search for in vitro assays that
helps to establish a correlation between clinical tumor
outcome and T cell responses elicited by anti-TTx in
cancer patients, we performed a series of functional as-
says with T cells obtained from a breast cancer patient
before and after anti-TTx that were stimulated in vitro
with two types of DCs pulsed with TAAs.
Our results suggest that the stimulation of T cells with
Type I alpha DCs derived in two days (2d-aDCs) pulsed
with TAAs allowed us to demonstrate that anti-TTx res-
cues T cells from the profound unresponsiveness status
typically observed in patient T cells before treatment,
this recovery of T cell function could be explained in
part by the production of IL-12 by 2d-aDCs (data not
show). The T cell responsiveness after anti-TTx was
reflected in the recovery of TCR internalization; expres-
sion at the cell surface of T cell activation markers; acti-
vation of effector T cells specific for several TAAs and in
the expansion in peripheral blood of T cells specific for
TAAs that were present in the tumor infiltrate prior
anti-TTx.
Methods
Patient and volunteers PBMCs isolation
This study was approved by the ethics committee of the
Medical School – Universidad Nacional de Colombia
(CE-14, 9 August 2008, Act. 107). The patient MCC-002
and all healthy donors signed an informed consent form
before blood samples were taken. Heparinized blood
samples were obtained from healthy volunteers (60 mL).
From patient MCC-002 a leukapheresis was obtained be-
fore and after eight months of having finished the treat-
ment (Additional file 1: Figure S1). PBMCs were purified
using density gradient centrifugation with Ficoll-Paque
PLUS (GE Healthcare Life Sciences) and cryopreserved
in freezing medium containing 50 % RPMI-1640 + 40 %
fetal bovine serum (FBS) (Gibco - Life Technologies) +
10 % Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St.
Louis, United States) at a maximum concentration of 107
cells/mL using controlled freezing temperature with an
isopropanol filled container and afterwards stored in li-
quid nitrogen until use. The viability of cells was evaluated
directly with 0.4 % Trypan Blue (Life Technologies) and/
or with flow cytometry (FC) using LIVE/DEAD Fixable
Aqua Dead Cell Stain Kit (Life Technologies).
T cell purification
CD4+ and CD8+ naïve T cells were purified using
MACS cell separation with Naïve T CD4+ Cell Isolation
Kit II and Naïve CD8+ Cell Isolation Kit (Miltenyi
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Biotec, Germany) system with magnetic labeled anti-
bodies following manufacturer’s protocol, briefly PBMCs
were resuspended in MACS buffer (RPMI-1640 +
0.5 mM EDTA + 1 % FBS) and labeled with correspond-
ing antibody cocktail, after cells were washed in MACS
buffer, they were pass-through in a humidified (MS) col-
umn. Positive cells were washed twice and cell purity
was verified by flow cytometry with a purity > 95 %.
T cells stimulation
Two different T cell stimulation methods were used
(Additional file 2: Figure S2). Total PBMCs were
enriched with 2d-stDCs or 2d-aDCs based on the meth-
odology of Martinuzzi et al., [13]. Briefly, 106 PBMCs
were cultured with IL-4 and GM-CSF as described by
Scandella [15] in the presence of 5 μM of tumor-
associated antigens (TAAs), HLA-A*02:01 restricted
viral peptides (CMV, FLU or EBV) for 24 hours and sub-
sequently maturated using either 2d-aDCs or 2d-stDCs
maturation cocktails [12, 16], with the addition of 5 μM
of the corresponding peptide(s) for 6 days (Additional
file 2: Figure S2A); in some experiments unpulsed DCs
were used as control in order to determine the basal
level of T cell stimulation. The second method using
purified CD4+ or CD8+ naïve T cells is based on the
methodology published by Moser et al., [14]. Briefly,
purified monocytes were differentiated into 2d-stDCs or
2d-aDCs, pulsed or unpulsed with TAA peptide(s)
(5 μM each) and subsequently cultured with purified
CD4+ or CD8+ naïve T cells for 14 days at a ratio of
50:1 (T cell: DCs) in serum free AIM-V culture media
(Life Technologies, Carlsbad, CA, United States). After
14 days of priming, CD4+ or CD8+ T cell cultures were
boosted with corresponding peptide-pulsed 2d-stDCs or
2d-aDCs and cultured for 6 additional days (Additional
file 2: Figure S2B). For polyclonal stimulation, 5×106
PBMCs/mL were stimulated in different conditions; (i)
2d-aDCs induced in PBMCs in situ; (ii) combining 2d-
aDCs with T cell activation/Expansion kit (antiCD3/
CD28/CD2 micro beads - Miltenyi Biotec) for 24 h after
differentiation of 2d-aDCs; (iii) only with T cell activa-
tion/Expansion kit; and (iv) PBMCs cultured without
stimulation for 3 days as control.
Flow cytometry and cytokine quantification
For the staining procedure, cells were collected and
stained in a final volume of 50 μL of staining buffer
(PBS + 1 % FBS) for 30 min at 4 °C and washed with
staining buffer before flow cytometry acquisition. Puri-
fied T cells or total PBMCs were stained with the follow-
ing fluorescent antibodies: CD3, CD4, CD152 (CTLA-4),
BTLA, PD1 or CD69 (Biolegend, San Diego, United
States) or CD8 (eBiosciences, San Diego, United States),
CD45RO, CD45RA, CD62-L (BD), CD154 (CD40L)
(eBiosciences, San Diego, United States), CD95 (Fas), or
CCR7 (R&D Systems). Cytokine secretion (TNF-α,
IFN-γ, IL-6 or IL-12p70) was measured in the culture
supernatants using human Th1/Th2 and Inflammatory
CBA kits (BD Biosciences) following manufacturer’s
protocol. All samples were acquired using the FAC-
SAria II (BD Biosciences) at the Universidad Nacional
de Colombia; cytometric bead array (CBA) data was
analyzed using FCAP Array™ Software (BD). The flow
cytometry data were exported in FCS file format v3
and analyzed using FlowJo software (Treestar Inc.).
The graphics and statistics were generated using
Prism v5 software (Graph Pad).
Peptide synthesis
Three peptides from extracellular domains of HER2/neu
(HER2/neu42–56, 98–114, and 328–345) and three peptides
from intracellular domains (HER2/neu776—790, 927—941,
and 1166–1180) [17], HLA-A*02:01 restricted viral
(NLVPMVATV – CMVPP65, GLCTLVAML – EBV280–288
BMFL1, and GILGFVFTL – influenza M1), and
TAAs HER2/neu369–377 (KIFGSLAFL), HER2/neu689–697
(RLLQETELV), HER2/neu435–443 (ILHNGAYSL), and
NY-ESO1157–165 (SLLMWITQV) peptides were gener-
ated through solid phase peptide synthesis (viral pep-
tides were purchased to 21st Century Biochemicals,
CPC Scientific) and TAAs peptides were synthesized at
the Fundación Instituto de Inmunología de Colombia -
FIDIC), with purity >85 % analyzed by mass spectrometry.
The lyophilized peptides were dissolved in DMSO and di-
luted in PBS to a working concentration of 2 mM each.
Tetramer staining
Biotinylated HLA-A*02:01 tetramers were synthesized
by CPL at the Lawrence Stern Laboratory, University of
Massachusetts Medical school. The tetramers were la-
beled with streptavidin-PE or streptavidin Alexa 700
(Invitrogen™ Life Technologies) at a 4:1 molar ratio in a
stepwise addition before use. For tetramer staining
process, cells were labeled with 2 μg/mL of corresponding
tetramers during 2 h at 37 °C, followed by the addition of
the corresponding antibody cocktail for surface markers
added as described above. In Fig. 2, CD8+ T cells were la-
beled with HER2/neu369–377 APC MHC dextramer kindly
gifted by Immudex (Copenhagen – Denmark).
TCR Vβ quantification and CDR3 sequence
To compare the 24 families of TCR Vβ repertoire in
tetramer positive and negative CD8+ T cells, ex vivo
PBMCs were stained with HER2/neu369–377 biotin tetra-
mer labeled with streptavidin Alexa fluor 700 as de-
scribed above in 8 different tubes, followed by TCR Vβ
family label using IOTest Beta Mark TCR V Kit (Beckman
Coulter, Pasadena, United States) with each antibody
Bernal-Estévez et al. BMC Cancer  (2016) 16:591 Page 3 of 13
cocktail (vials A to H) and anti-CD8 PE-Texas Red (eBios-
ciences, San Diego, United States); a minimum of 5×104
CD8+ T cells were acquired, and the percentage of each
family in HER2/neu specific CD8+ T cells was analyzed
with FlowJo software (Treestar, Ashland, United States).
For CDR3 sequences, 2×107 PBMCs collected before and
after anti-TTx were used to obtain genomic DNA using
Wizard® Genomic DNA Purification Kit (Promega Corp.,
Madison, United States) following manufacturer’s proto-
col. For the CDR3 sequencing of TILs, two tumor slices
(3 μm thick each) were obtained from tumor resection by
surgery of the MCC-002 patient fixed-formalin paraffin
embedded (FFPE). The DNA from the FFPE sample
(extracted by ImmunoSEQ) and DNA from the two
PBMCs samples were verified and then sequenced by
ImmunoSEQ service (Adaptive Biotechnologies, Seattle,
United States), raw data can be found in Additional file 3:
Table S1.
Results
The anti-tumor therapy reestablishes T cell
responsiveness
Experimental evidence suggests that cancer patients -
similar to what has been described in some chronic viral
infections - experience a reduction in T cell function
[4, 18], in order to determine the effect of anti-TTx
on the responsiveness of the T cell compartment, the
capacity in MCC-002 patient’s T cells to respond ei-
ther to a TCR stimulation or to a pro-inflammatory
stimuli was compared in PBMCs from blood samples
taken before and after anti-TTx (see patients details
in Additional file 1: Figure S1). For this, we estab-
lished first an in vitro assay using PBMCs from
healthy individuals stimulated with a mixture of anti-
CD3, anti-CD28 and anti-CD2 conjugated to micro
beads in order to measure the degree of TCR intern-
alization and expression of CD69, CD25, and CD154
on T lymphocytes of normal individuals. The re-
sponse to TCR stimulation in T cells from healthy
donors was then compared with those from the pa-
tient before and after anti-TTx. TCR internalization
in response to stimulation was determined by the
mean fluorescence intensity (MFI) of CD3. This
measurement showed that patient’s T cells prior ther-
apy had a limited capacity to internalize the TCR
compared to cells from healthy donors. Notably, the
TCR internalization was 10 times higher after anti-
TTx than before therapy (MFI values before and after
anti-TTx were 3266 and 328 respectively – Fig. 1a)
suggesting that this function was recovered after anti-
TTx. The low capacity of TCR internalization ob-
served in cells prior anti-TTx was accompanied by a
limited expression of CD69, CD25, and CD154 in re-
sponse to TCR stimulation compared with surface
levels of these molecules on stimulated cells from
healthy donors (Fig. 1b and Additional file 4: Figure
S3 respectively). Likewise, to TCR internalization after
anti-TTx the cells recovered the expression of these
three molecules to levels similar to those found in
cells from healthy donors (Fig. 1a, b and Additional
file 4: Figure S3). Interestingly, the secretion of IFN-γ,
IL-8, IL-1β, and IL-6 in response to TCR stimulation
showed that before anti-TTx the cells had a deficit to
secrete these cytokines (Fig. 1c), however, after anti-
TTx the T cell responsiveness measured in terms of
IFN-γ and IL-8 secretion was recovered (Fig. 1c). Fi-
nally, whereas induction of 2d-aDCs in situ in cells
from healthy individuals showed in culture superna-
tants a high concentration of IFN-γ, IL-8, IL-1β, and
IL-6 that was not observed in cells of the patient be-
fore treatment, the induction in situ of 2d-aDCs in
cells after anti-TTx elicited levels of these cytokines
similar to those detected in cells from healthy individ-
uals (Fig. 1c). Altogether, these results indicate that
anti-TTx in this patient restores the ability of T cells to re-
spond to TCR stimulation and to a pro-inflammatory
stimulus provided by 2d-aDCs.
2d-aDCs helps revealing responsiveness of tumor specific
CD8+ T cells induced by anti-TTx
To explore the effect of anti-TTx in favoring the respon-
siveness of the T cell compartment in breast cancer pa-
tients, the expansion of CD8+ memory T cells [7] that
recognize HLA-A*02:01 restricted epitopes from HER2
and NY-ESO 1 was analyzed in PBMCs before and after
anti-TTx in our patient stimulated with 2d-aDCs or 2d-
stDCs as control APCs using two different in vitro
systems (Additional file 2: Figure S2). The first in vitro
system is based on the method originally described by
Martinuzzi et al., [13] to study the responsiveness of
antigen specific memory T cells in peripheral blood
(Additional file 2: Figure S2A) patient’s PBMCs were
stimulated for six days with either 2d-stDCs or 2d-aDCs
derived in situ with cytokines and pulsed with a pool of
three HER2/neu and one NY-ESO 1 HLA-A*02:01 re-
stricted epitopes. We did not observe ex vivo difference
in the percentage of HER2- or NY-ESO 1-specific mem-
ory T cells among total CD8+ cells in samples obtained
before and after therapy (data not shown). In contrast,
in cultures stimulated with peptide-pulsed 2d-aDCs, the
percentage of HER2/neu369–377 (KIFGSLAFL) tetramer-
positive TEMRA CD8+ T cells (CD62-Llow/CD45ROlow/
CD45RAhigh) was higher after than before anti–TTx
(3.2 % and 0.01 % respectively). This expansion after
treatment was not observed when the cultures were
stimulated with peptide-pulsed 2d-stDCs (percentages
before and after anti-TTx were 0.06 % and 0.02 % re-
spectively) (Fig. 2a). These results suggest that 2d-aDCs
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are more efficient than 2d-stDCs in evidencing the re-
sponsiveness of anti-tumor memory T cells elicited by
anti-TTx. We failed to detect in PBMCs from this pa-
tient CD8+ memory T cells specific for NY-ESO 1157–165
epitope (SLLMWITQV) using 2d-aDCs or 2d-stDCs
(Additional file 2: Figure S2A and data not shown).
The second in vitro system is based on methodology
used by Moser et al., to estimate the repertoire of antigen
specific naïve T cells present in peripheral blood [14]. To
do this, naïve CD4+ and CD8+ T cells obtained from
blood samples before and after therapy were primed inde-
pendently with either 2d-stDCs or 2d-aDCs pulsed with
HER2/neu369–377 or NY-ESO 1157–165 peptides. After
14 days of priming, the cultures were boosted with the
corresponding DCs pulsed with peptide for one additional
week (Additional file 2: Figure S2B). Stimulation of naïve
T cells with peptide pulsed DCs showed that naïve T cells
specific for NY-ESO 1 (SLLMWITQV) HLA-A*02:01 epi-
tope from samples after anti-TTx were primed and
boosted more efficiently by 2d-aDCs than naïve T cell
preparations obtained before therapy (2.24 % vs. 1.4 %,
respectively). 2d-stDCs did not induce the expansion of
NY-ESO 1-specific CD8+ T cells compared with unpulsed
DCs (2.03 % and 3.25 %, respectively) (Fig. 2b). After sev-
eral attempts, no expansion of HER2/neu369–377 (KIFG-
SLAFL)-specific CD8+ T cells using this in vitro system
was observed (data no shown). Thereafter, we quantified
IFN-γ and TNF-α cytokine secretion in both CD8+ and
CD4+ T cell culture supernatants (delta of peptide-pulsed
DCs minus unpulsed DCs). IFN-γ and TNF-α were se-
creted in higher concentrations by patient’s cells after
anti-TTx stimulated with peptide-pulsed 2d-aDCs. In con-
trast, we observed that in patient’s naïve T cells (CD8+ or
CD4+), 2d-stDCs induced similar levels of cytokine secre-
tion in samples obtained before or after anti-TTx (Add-
itional file 5: Figure S4). These results suggested that after
anti-TTx, 2d-aDCs successfully prime and boost the naïve
repertoire of anti-tumor CD4+ and CD8+ T cells present
in the peripheral blood of this breast cancer patient.
Anti tumor-therapy induces the expansion and activation
of tumor specific effector CD8+ T cells
To assess efficacy of anti-TTx in fostering the expansion
of tumor specific T cells, we compared in blood samples
of this breast cancer patient before and after anti-TTx,
the frequency and the memory phenotype of CD8+ T
cells specific for several HLA–A*02:01 restricted tumor
epitopes (TAAs): Initially, we evaluate the expansion of
Her2/neu specific T cells in total PBMC in response to
2d-aDCs pulsed with a pool of three different HLA-
A*02:01 restricted peptides (HER2/neu369–377 KIFGSLAFL,
HER2/neu689–697 RLLQETELV, and HER2/neu435–443
Fig. 1 Chemotherapy restores deficient immune response in breast cancer patient. a. Representative contour plots of SSC-A vs CD3 in Lymphocyte
cells (by SSC-A vs FSC-A) after 72 h of polyclonal stimulation with anti-CD3/CD28/CD2 micro beads, 2d-aDCs or a combination of micro beads in
addition to 2d-aDCs in healthy donors (n = 12), and breast cancer patients (n = 8) (before and after anti-TTx), numbers inside correspond to MFI of
CD3 in lymphocyte gate (SSC-A vs FSC-A). b. Contour plots of CD69 percentage expression in T cells (CD3+) as in panel A, numbers correspond to
the percentage of CD69 expressing cells in CD3+ T cells. c. Delta (from left to right) of IFN-γ, IL-8, IL-1β, and IL-6 cytokines relative to unstimulated con-
trol in healthy donors (Dashed bars) (n = 6) and MCC-002 breast cancer patient (before and after anti-TTx white and black bars respectively), bars show
SEM. X: not detected. Results of experiments presented in panel c are representative of three performed
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ILHNGAYSL) and compared with the expansion of
viral specific T cells (cytomegalovirus CMV pp65495–503
NLVPMVATV; Influenza Matrix protein 1 FLU58–66
GILGFVFTL, and EBV BMLF1 protein EBV280–288
GLCTLVAML). We evidence a small expansion of TAA
and viral specific CD8+ T cells after 6 days of stimulation
with peptide pulsed 2d-aDCs in PBMCs obtained after
anti-TTx (Fig. 3a), in contrast, we observe a different dis-
tribution of naïve and memory sub-populations between
TAA vs viral specific T cells, in response to peptide pool
viral specific T cells have a high proportion of TEM and
TEMRA phenotype, compared to TAA specific T cells be-
fore anti-TTx. The phenotype of TAA specific T cells
change in response to anti-TTx, with a similar distribution
of viral specific T cells (Fig. 3b). To further characterize
the immune-phenotype of tetramer positive CD8+ T cells
after in vitro expansion with 2d-aDCs, we evaluated the
expression of three different inhibitory receptors (PD1,
BTLA and CTLA-4) on tetramer positive cells [19] and
compared with the expression of these receptors in total
CD8+ T cells; we found a substantial fold increase only in
CTLA-4 expression in TAA specific CD8+ T cells after
compared to before anti-TTx (43 before- to 58 after anti-
TTx) with no major changes in cells specific for viral anti-
gens or the expression of PD1, or BTLA (Fig. 3c).
To evaluate the specificity of the anti-tumor immune
response against each TAA elicited by anti-TTx, the pro-
file of tetramer positive CD8+ T cells specific to four in-
dividual tumor epitopes was measured ex vivo and in
vitro (Fig. 4a left panels). This profile was compared to
that of tetramer positive CD8+ T cells specific for three
HLA-A*02:01 restricted viral epitopes CMV pp65495–503;
FLU58–66 (Fig. 4a right panels) and EBV 280–288 (data not
shown). There were not major differences ex vivo in the
percentages of CD8+ tetramer positive cells specific for
tumor or viral antigens in samples obtained before and
after anti-TTx (Fig. 4a). On the other hand, when
PBMCs were stimulated with in situ derived 2d-aDCs in
the presence of each TAA, the frequency of tetramer
positive CD8+ T cells showed some increase in response
to HER2/neu369–377 (KIFGSLAFL) epitope (from 0.42 %
before to 0.72 % after anti-TTx) and to lower extent in
Fig. 2 2d-aDCs induce expansion and activation of CD8+ NY-ESO1 and HER2-specific T cells in a breast cancer patient after anti-TTx. a. Percentage
of TEMRA HER2/neu-specific CD8+ T cells subsequent to induction of in situ 2d-aDCs or 2d-stDCs in total PBMCs (MCC-002) induced for 6 days
comparing samples obtained before (left column) and after anti-TTx (right column) pulsed with HER2/neu369–377 peptide. b. Percentage of TEMRA
NY-ESO 1-specific CD8+ T cells from patient MCC-002 derived from naïve CD8+ T cells in co-culture with 2d-aDCs or 2d-stDCs-pulsed/unpulsed
with NY-ESO 1157–165 and stimulated with DCs for 14 days and boosted with corresponding DCs for 6 additional days, comparing samples obtained
before (left column) and after anti-TTx (right column). X: not done. Results of experiments presented in panels a and b are representative of
two performed
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response to NY-ESO1 (from 0.45 % to 0.61 % before vs.
after anti-TTx). Neither before not after the anti-TTx,
CD8+ T cells specific for viral antigens exhibited signifi-
cant expansion upon stimulation in vitro with 2d-aDCs
pulsed with each viral epitope (Fig. 4b).
The analyses ex vivo of the distribution of naïve and
memory T cell sub-populations within tetramer positive
CD8+ T cells specific for tumor or viral antigens did not
show major differences among samples obtained before
or after anti-TTx (Fig. 4c right and left panels). As ex-
pected a remarkable expansion of TEMRA CD8+ T cells
was observed in samples before and after anti-TTx upon
stimulation of the cells in vitro for six days with CMV,
FLU (Fig. 4d right panels) and EBV (data not shown)
viral peptides. That similar responsiveness of CD8+ T
cells specific to tumor antigens was observed after indi-
vidual in vitro stimulation with four different tumor epi-
topes only in samples obtained after anti-TTx and was
not evident in cells before anti-TTx (Fig. 4d left panels),
lead us to argue that the anti-TTx in this patient effi-
ciently promotes the responsiveness of tumor specific ef-
fector CD8+ T cells (TEMRA). Based on the increase of
CTLA-4 expression in TAA specific CD8+ T cells after
anti-TTx, we evaluated the expression of CTLA-4 on
tetramer positive cells; we found a substantial increase
in the percentage of CTLA-4 expression in HER2/
neu369–377; NY-ESO 1 and FLU specific CD8+ T cells
after compared to before anti-TTx (12.4 % before- to
31.9 % after anti-TTx; 10.1–19.7 % and 10.2–19.0 % re-
spectively) with no major changes in cells specific for
CMV (15.8 % prior- to 12.8 % post-treatment) (Fig. 4e).
Expansion of TAA specific CD8+ T cells after anti-tumor
therapy correlates with the T cell repertoire of tumor
infiltrating lymphocytes
To assess changes in the repertoire of TAA specific
CD8+ T cells in peripheral blood induced by anti-TTx
and their relationship with tumor infiltrating lympho-
cytes, we compared to ex vivo by FC the TCR-Vβ
repertoire of HER2/neu369–377 tetramer positive CD8+
T cells present in PBMCs from the patient before and
after anti-TTx. The percentage of 24 Vβ families in
tetramer positive and tetramer negative CD8+ T cells
before and after anti-TTx is summarized in Fig. 5a
right panel. This result showed the enrichment in
tetramer positive cells after anti-TTx of the Vβ families
Vβ7.1, Vβ9, Vβ5.1, Vβ20, Vβ13.1, Vβ5.2, and Vβ04
(Fig. 5a). The specificity and the frequency of T cells is
generated by somatic rearrangement of TCR genes and
mainly focused on the CDR3 region. This has been
Fig. 3 Anti-TTx induces enrichment of CTLA-4 in tumor specific T cells. a. Expression of tetramer positive (pool of Her2/neu or viral tetramers) in
CD8+ T cells after 6 days of stimulation with aDCs derived in situ and pulsed with a combination of HLA-A*02:01 restricted peptides (TAA peptide
pool HER2/neu369–377, HER2/neu689–697 and HER2/neu435–443, or viral peptide pool CMVPP65, EBV280–288, and FLU58–66). b. Pie chart of naïve and
memory sub-populations distribution in tetramer positive CD8+ T cells (TAA or viral specific) after stimulation with pulsed 2d-aDCs before and
after anti-TTx (Blue; naïve, Grey; TCM, yellow; TEM; and green TEMRA). c. Fold increase of inhibitory receptors (PD1, BTLA, and CTLA-4) expression
between tetramer positive over tetramer negative CD8+ T cells after stimulation with peptide pulsed 2d-aDCs, obtained before (white bars) and
after (black bars) anti-TTx
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Fig. 4 (See legend on next page.)
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evaluated by spectratyping in combination with family
quantification of TCR-Vβ by FC in cancer patients [20]
making these systems useful for T cell identification, but
recent techniques can sequence the CDR3 region allowing
the quantification of each TCR at a gen level [21]. This
technology in combination with TAA MHC-class I tetra-
mers can be relevant for the evaluation of TAA specific T
cells in response to anti-TTx. In order to establish the
identity of these TCRs we sequenced the CDR3 region
and estimated the copy number of encoding transcripts in
PBMCs samples obtained before and after anti-TTx
from our breast cancer patient. To evaluate the
tumor infiltration capacity of these cells we per-
formed a similar analysis in tumor infiltrating lym-
phocytes (TILs) using fixed-formalin paraffin
embedded (FFPE) tumor slices. Figure 5b shows the
profile of TCR Vβ families (left heat map) and TCR
Vβ genes (right heat map) in blood before and after
anti-TTx and in TILs with those at the highest fre-
quencies highlighted in black squares. Whereas the
heat map of Vβ families and defined genes expressed
by T cells in blood samples before and after therapy
evidenced great variability, in TILs, Vβ16 and Vβ04
families (Vβ16-01 and Vβ04-02 genes) were present
at high frequency (Fig. 5b heat map lower rows).
Finally, in trying to correlate specificity of TILs with
expansion of CD8+ T cells specific for HER2/neu369–
377 detected in blood by FC, we correlated frequency
of Vβ families expressed by tetramer positive cells
(Fig. 5a) with the frequency of the same Vβ families
in TILs detected by the TCR CDR3 sequence (Fig. 5b).
Interestingly, we found a better correlation (r2) of
Vβs expressed by TILs with that of HER2/neu369–377
specific CD8+ T cells in blood samples after than be-
fore anti-TTx (r2: 0.47 and r2: 0.15 respectively) with
a high correlation of Vβ04 (Fig. 5c). These results
suggest that the anti-TTx induced an increase of
HER2/neu369–377 specific CD8+ T cells capable of in-
filtrating the tumor and that this increase can be de-
tected in the peripheral blood of this patient.
Discussion
Previous results obtained by our group showed that
alpha DCs generated in two days (2d-aDCs) has a
mature phenotype similar to those generated by Mail-
liard et al., in seven days [12] and also similar to
standard DCs generated in seven (7d-stDCs) [12, 22]
or two (2d-stDCs) days [23, 24] (DB et al., manu-
script in preparation). One of the major functional
characteristics of aDCs is the secretion of IL-12 and
we found that 2d-aDCs secrete IL-12 more efficiently
than 2d-stDCs (data not shown) suggesting that 2d-
aDCs are not in an exhausted state [25]. The produc-
tion of IL-12 by DCs is of paramount importance for
plasma cell differentiation; for antibody production
promoted by follicular CD4+ T-helper cells (TFH)
[26] and for the generation of anti-tumor specific
CD8+ T cells [27–29] both in vitro [30] and in vivo
[31], hence, IL-12 production by DCs is considered
one important requirement for DC-based cancer im-
munotherapy. In this work, we use 2d-aDCs as a tool
for assess Th1 response against TAAs and to monitor
the responsiveness of anti-tumor specific T cells in-
duced in cancer patients by anti-TTx.
To evaluate the immune response of the T cell
compartment in patients with breast cancer, we estab-
lished an in vitro method of polyclonal stimulation of
T cells to assess the responsiveness of T cells charac-
terized by internalization of CD3, the expression of
different activation markers and secretion of Th1
cytokines. This system enabled us to determine that
before the anti-TTx, T cells obtained from a breast
cancer patient who is free of disease after several
years of completion of the anti-TTx, exhibited a pro-
nounced defect in responsiveness to stimuli and that
anti-TTx efficiently rescued the sensitiveness of T
cells to TCR stimulation. The responsiveness of the T
cell compartment to the stimulus elicited by anti-TTx
was measured through different immunological read-
outs such as TCR internalization, surface expression
of activation markers and secretion of cytokine that
(See figure on previous page.)
Fig. 4 Anti-TTx induces the expansion, differentiation and CTLA-4 expression in Her2/neu369–377 tumor specific CD8+ T cells. a. Representative contour
plots of tetramer specific CD8+ T cells staining for HER2/neu369–377 (KIFGSLAFL), HER2/neu689–697 (RLLQETELV), HER2/neu435–443 (ILHNGAYSL) and
NY-ESO 1157–165 (SLLMWITQV), and two tetramers for viral antigens (NLVPMVATV – CMVPP65, and GILGFVFTL – influenza M1 FLU58–66), stained ex vivo in
PBMCs from a breast cancer patient before and after anti-TTx in purified CD8+ T cells. The number inside the plots represents the percentage of
tetramer-specific CD8+ T cells. b. Representative contour plots of tetramer specific CD8+ T cells after 7 days of in vitro stimulation of PBMCs with the
corresponding peptide pulsed 2d-aDCs, the number inside the plots represents the percentage of tetramer-specific CD8+ T cells. Results
of experiments presented in panels a, and B are representative of two performed. c. and d. Representative pie charts of ex vivo (c) or
after in vitro PBMC stimulation (d), as described in a and b, with the percentage of the phenotype of naïve and memory sub-
populations in CD8+ tetramer positive T cells for four TAAs and two viral HLA-A*02:01 peptides before and after anti-TTx. Blue; naïve, Orange; TSCM,
Grey; TCM, yellow; TEM; and green TEMRA. Results of experiments presented in panels c and d are representative of two performed. e. Representative
contour plots of CTLA-4 vs CD8 in tetramer positive CD8+ T cells for HER2/neu369–377 (KIFGSLAFL) and NY-ESO1157–165 (SLLMWITQV) tetramer + CD8+ T
cells for two viral antigens (NLVPMVATV – CMVPP65, and GILGFVFTL – influenza M1 FLU58–66), in PBMCs stimulated with in situ 2d-aDCs from PBMCs
obtained before and after anti-TTx as described in a and b. Results of experiments presented are representative of two performed
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were low in cells before therapy but that in T cells from
the patient after anti-TTx reached similar levels to those
observed in stimulated T cells from healthy individuals
(Fig. 2). These results support the adjuvant effect of the
anti-TTx in the T cell compartment of breast cancer pa-
tients proposed by others in preclinical studies of cancer
mouse models [32]. Based on these observations, we are
currently analyzing this phenotype in a series of patients
with breast cancer before and after treatment with neo-
adjuvant chemotherapy with anthracyclines (doxorubicin)





Fig. 5 Increased correlation of TCR Vβ families between tumor infiltrating lymphocytes and HER2/neu tetramer CD8+ T cells after chemotherapy.
a. Dot plot example of an ex vivo flow cytometry analysis of TCR-Vβ families 13.2, 4 and 7.2 in CD8+ T cells HER2/neu369–377 tetramer negative vs.
tetramer positive from before and after anti-TTx cells, each gate represents one TCR-Vβ family, PE positive correspond to Vβ13.2, the double
positive cells corresponds to family Vβ4, and FITC positive corresponds to family Vβ7.2, numbers correspond to percentage of each family, left;
Delta of the percentage of each of 24 families (after minus before therapy) in total CD8+ T cells (empty bars) or tetramer positive CD8+ T cells
(black bars), right. b. Heat map of sequenced TCRs from total PBMCs (before and after anti-TTx) and Tumor Infiltrating Lymphocytes (TILs) from
FFPE tumor tissue slice. Arrows points insert of highly expressed of TCR Vβ families and genes in TILs. c. Correlation plots of Vβ families of HER2/
neu369–377 tetramer positive cells (red corresponds to before anti-TTx sample, and blue corresponds to after anti-TTx sample)
analyzed by flow cytometry vs. the percentage of Vβ families obtained from TILs. Pre-chemotherapy r2: 0.164, p value: 0.017, post-chemotherapy
r2: 0.477, p value: <0.0001 (linear regression analysis)
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In order to evaluate the functional capacity of 2d-
aDCs to induce expansion of TAA-specific T cells, two
in vitro culture conditions were used (Additional file 2:
Figure S2); the first condition was used to determine the
degree of expansion and activation of T cells that
recognize different TAA present in the pool of memory
CD8+ T cells and the second to assess the response of
naïve T lymphocytes to priming in vitro with these
TAAs. As described previously, the anti-TTx resulted in
the recovery of the T cell responsiveness to a polyclonal
stimulus. To demonstrate the effect of anti-tumor ther-
apy in response of antigen specific T cells, it was com-
pared in both culture systems the capacity of anti-TTx
to favors the expansion in vitro of TAA specific T cells
after chemotherapy using as APCs 2d-aDC or 2d-stDCs
to stimulate T cells. The results suggest that 2d-aDCs
are more efficient than 2d-stDCs in evidencing the ex-
pansion of TEMRA CD8+ T cells specific for TAAs fa-
vored by anti-TTx (Fig. 2). Notably, the expansion of
naïve T cells in post-chemotherapy samples primed in
vitro with 2d-aDCs pulsed with TAAs increased IFN-γ
and TNF-α in supernatants of CD8 + T cells (Additional
file 5: Figure S4). Furthermore, the stimulatory capacity
of the anti-TTx on CD8+ T lymphocytes was evidenced
in the expansion of TEMRA CD8+ T cells specific for
HER2/neu369–377 (KIFGSLAFL) epitope only in samples
after anti-TTx contrary to the conserved response to
viral antigens before and after anti-TTx (Fig. 4). Also
HER2/neu specific T cells expressed high levels of
CTLA-4 (Fig. 4e), interestingly the expression of CTLA-
4 as a biomarker of stimulated CD8+ T cells has been
associated with a favorable clinical response in patients
in immunotherapy treated with anti-PD-L1 [33]. These
results are consistent with the recent analysis of Speiser
and colleagues in the sense that the expression on CD8+
T cells of molecules such as PD-1, BTLA and CTLA-4
does not mark necessarily cells with a reduced T cell
function but rather mark different subsets of activated T
cells linked to positive clinical outcomes [19]. Together
these results suggest that in this patient with breast can-
cer, 2d-aDCs allow the expansion of tumor specific T
cells favored by chemotherapy and they could be used to
monitor the immunological effects of the anti-TTx on
tumor specific T cells. Hence we propose that the ob-
served competence as APCs of 2d-aDCs derived in situ
from PBMCs will be a useful system for monitoring
tumor specific T cells using small volumes of blood in
patients with cancer in anti-tumor treatment.
Different studies using next generation sequencing
(NGS) show an anti-tumor effect of anti-TTx on the T
cell repertoire in different tumors such as lung [34] and
colorectal cancer [35]. Combining strategies proposed by
Pilch et al., [20] and Robins et al., [21] we analyzed the
frequency of TCR Vβ by FC and the identity of TCR
CDR3 through NGS to optimize the assessment of TCR
repertoire of anti-tumor cells in the patient MCC-002.
To establish the identity of TILs we analyzed the Vβ rep-
ertoire of TILs in the diagnosis biopsy using FFPE as
source of tumor tissue followed by CDR3 sequencing
using NGS. The repertoire of TILs was then compared
to that obtained ex vivo from blood samples before and
after anti-TTx. The results of the analysis of the CDR3
repertoire in the biopsy and in blood before and after
therapy lead us to suggest that anti-TTx favors the ex-
pansion in peripheral blood of tumor specific T cells that
infiltrate the tumor before therapy. Altogether our re-
sults suggest that the use of FFPE as a source of tumor
tissue combined with NGS and the detection and func-
tional analysis of T cells that recognize TAAs in blood
using fluorescent tetramers may be useful to monitor
both the dynamics of the traffic of TILs between tumor
and peripheral blood and for the assessment of the func-
tional status of these cells in peripheral blood during
anti-TTx.
Evaluating to what extent clinical response to can-
cer is attributable to the activation of anti-tumor T
cells induced by chemo- or radiotherapy is currently
a matter of interest of numerous clinical studies [36].
Similar to what was shown in patients with colorectal
cancer under radiotherapy [37]; in the present study
using 2d-aDCs we found that the anti-TTx stimulates
CD8+ anti-tumor T cells. The use of these cells as
APCs reveals a stimulatory effect of anti-TTx on the
responsiveness of CD8+ T cells specific for TAAs in
breast cancer patients. The results presented here,
were possible by the considerably amount of cells ob-
tained from an ideal patient (Her2/neu+++, HLA-
A*02:01), are limited by the number of patients that
could be followed up with this deep immunological study.
The recovery of the unresponsiveness observed prior anti-
TTx is reflected in the improvement in T cell function. As
a whole, our results suggest that evidencing the adjuvant
effect of the anti-TTx in breast cancer that can be ex-
plored in other tumors.
Conclusions
The anti-tumor therapy benefits the immune response
of the treated patient. This benefit was evidenced in
vitro by increasing the T cell responsiveness and expand-
ing tumor-specific CD8+ T cells in peripheral blood with
a functional phenotype of memory effector cells. This in
vitro approach can be implemented in a cohort of breast
cancer patients in order to evidence the effect of other
chemotherapy regimens that includes anthracyclines,
known for inducing immunogenic cell death in tumor
cells, and to establish a possible predictive marker for
clinical response.
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Additional files
Additional file 1: Figure S1. Timeline of MCC-002 treatment. A
63-year-old woman (MCC-002) was diagnosed with invasive ductal
breast carcinoma (stage II, T2N3M0) after a suggestive result in a
control process by mammography (BIRADS 6). After the realization of
the biopsy, the tumor is positive for HER2/neu (C-erb2), and NY-ESO
1, and negative for hormonal receptors (ER and PR), with compro-
mised axillary lymph nodes but no evidence of bone metastasis. This
patient was screened for HLA-A2 by flow cytometry that was con-
firmed by SSP-PCR for HLA-A*02:01. After signed informed consent, we
obtained by leukapheresis a preparation of 150 mL buffy coat enriched
in peripheral blood mononuclear cells (PBMC). This patient was
treated with modified radical mastectomy (MRM) of the left breast in-
cluding axillary
clearance (5 of 21 lymph nodes were compromised with tumor),
with no complications. After surgery (September 2008), the patient
was treated with 12 weekly doses of paclitaxel (150 mg) and was
programmed for one year of treatment with trastuzumab (440 mg
every three weeks) and four weeks of radiotherapy (2.5Gy daily). In
March 2009, after the fifth dose of trastuzumab and four doses of
radiotherapy, the patient experimented acute cardiac failure with a
ventricular ejection fraction (VEF) below 30 % (VEF on August 2008
prior surgery was 59 %). Because cardiac toxicity, the chemo- and
radio-therapy were suspended. The cardiac failure was managed
successfully with spironolactone (50 mg/daily) and furosemide
(40 mg/12 h). The follow-up mammographies were negative (BIRADS
2 for the contralateral breast). Finally, 8 months after the suspension
of anti-tumor treatment, a second leukapheresis was obtained in
order compare prior vs. after anti-TTx the effect of treatment on the
immune response using a number of experimental readouts. Currently,
MCC-002 maintains with a clinical complete response after 7 years of the
anti-tumor therapy suspension controlled with annual mammography.
(TIF 437 kb)
Additional file 2: Figure S2. Flowchart of the methodology used for cell
culture with 2d-aDCs and 2d-stDCs. A. Methodology for in situ induction of
2d-aDC and 2d-stDC in total PBMCs (based on the methodology of
Martinuzzi et al., [13]). PBMCs were stimulated for 24 h with IL-4 and
GM-CSF with peptide(s) and maturated with a combination of proin-
flammatory cytokines and TLR ligands for the corresponding DCs
with or without a new addition of the corresponding peptide(s) for
6 days. B. T cell stimulation scheme based on the methodology de-
scribed by Moser et al., [14]. Briefly, 2d-aDCs and 2d-stDCs were de-
rived from monocytes and cultured with purified autologous naïve
CD4+ or CD8+ T cells for 14 days and re-stimulated for 6 days with
peptide (5 μM)-pulsed 2d-aDCs or 2d-stDCs. (TIF 308 kb)
Additional file 3: TCR raw data sequence from PBMCs obtained before
and after therapy and TILs obtained from FFPE tumor. (XLSX 27054 kb)
Additional file 4: Figure S3. Expression recovery of CD25 and CD154
in T cells after chemotherapy. Fold percentage of CD25 (left) and CD154
(right) in CD3 positive T cells relative to un-stimulated PBMCs as
described in Fig. 5 in healthy donors (Dashed bars) (n = 3) and a breast
cancer patient (pre and post chemotherapy white and black bars
respectively), bars show SEM. Results of experiments presented are
representative of three performed. (TIF 175 kb)
Additional file 5: Figure S4. High IFN-γ and TNF-α secretion from CD8
+ and CD4+ T cells after anti-TTx when stimulated with 2d-aDCs. Delta of
IFN-γ and TNF-α concentration in pg/mL (pulsed minus unpulsed DCs
culture) in the supernatants of CD8+ and CD4+ T cells subsequent to
stimulation for 14 days, with boosting for 6 days in samples before and
after anti-TTx with 2d-aDCs or 2d-stDCs pulsed with HER2 peptides.
Results of experiments presented are representative of two performed, x
= data not detected. (TIF 317 kb)
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